Guo Kefang, Cang Jing
Department of Anesthesia, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Drug Des Devel Ther. 2016 Mar 30;10:1291-8. doi: 10.2147/DDDT.S103169. eCollection 2016.
In this study, novel tetrandrine-loaded chitosan microspheres were prepared by the emulsion cross-linking method. The systems were then characterized for physicochemical properties and in vitro drug release. In addition, the pharmacokinetics and tissue distribution of microspheres were further verified in animal models. Particle-size distribution indicated that the size of microspheres was within the range of 7-15 μm, with a median diameter of 12.4 μm. The drug loading and entrapment efficiency of the formulation were 34.6%±12.5% and 87.3%±9.7% (mean ± SD), respectively. In vitro release showed a typical sustained and long-term drug release behavior. The Higuchi equation was the model that fit best with release data. Maintaining a relatively constant plasma concentration in the long-term drug treatment is an outstanding pharmacokinetic advantage of tetrandrine microspheres in vivo. Moreover, compared with tetrandrine solution, tetrandrine microspheres produced a lower drug concentration in the heart, liver, and kidneys. This indicated that the microspheres used in this study were preferable for targeting lung tissue versus other tissues. No damage to the tissues of the lung was found in histopathological examination.
在本研究中,采用乳化交联法制备了新型载粉防己碱壳聚糖微球。然后对该体系的理化性质和体外药物释放进行了表征。此外,还在动物模型中进一步验证了微球的药代动力学和组织分布。粒径分布表明微球尺寸在7 - 15μm范围内,中位直径为12.4μm。该制剂的载药量和包封率分别为34.6%±12.5%和87.3%±9.7%(平均值±标准差)。体外释放呈现典型的持续长效药物释放行为。Higuchi方程是最符合释放数据的模型。在长期药物治疗中维持相对恒定的血浆浓度是粉防己碱微球在体内的一个突出药代动力学优势。此外,与粉防己碱溶液相比,粉防己碱微球在心脏、肝脏和肾脏中的药物浓度较低。这表明本研究中使用的微球相对于其他组织更适合靶向肺组织。组织病理学检查未发现对肺组织的损伤。